GRAIL Seeks FDA Approval for Galleri Multi-Cancer Test: A Breakthrough in Early Cancer Detection

GRAIL (GRAL) has submitted the final segment of its Premarket Approval application to the FDA for its Galleri multi-cancer early detection test. The test, recognized as a Breakthrough Device, is supported by data from the PATHFINDER 2 study and the NHS-Galleri trial. GRAIL operates in the healthcare sector, focusing on early cancer detection technologies.